Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03595228 · ClinicalTrials.gov registry record · Phase 2

BN Brachyury and Radiation in Chordoma

A Phase 2 study, sponsored by Bavarian Nordic.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target

NCT03595228: Completed Phase 2 study, sponsored by Bavarian Nordic.

NCT03595228 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03595228, a Phase 2 study, has completed, sponsored by Bavarian Nordic.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target

Study Summary

The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity is needed to proceed to stage 2.

Primary Outcome

Rate of subjects achieving a best response of either Complete Response or Partial Response per modified RECIST v1.1. A modified RECIST v1.1 assessment is based on targeted radiated lesion(s). Progression of a non-target lesion does not result in disease progression by the modified RECIST evaluation for this trial. Assessment for targeted radiated lesion(s): Complete Response (CR)=Disappearance of all target radiated lesions; Partial Response (PR)= \>=30% decrease in the sum of the longest diamet

Interventions

  • BIOLOGICAL BN-Brachyury plus radiation

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2018-10-31
Est. Completion 2022-01-25
Phase Phase 2
Bavarian Nordic

41 total trials

What the finished NCT03595228 record still lists

NCT03595228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 1 intervention - of which BN-Brachyury plus radiation is the first listed.

NCT03595228 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03595228 about?

NCT03595228 is a clinical study titled "BN Brachyury and Radiation in Chordoma". The goal of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity is needed to proceed to stage 2.

What is the current status of trial NCT03595228?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-10-31. Estimated completion is 2022-01-25.

What interventions are being tested in trial NCT03595228?

The interventions under investigation include: BN-Brachyury plus radiation (BIOLOGICAL).

Who is sponsoring clinical trial NCT03595228?

This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03595228's enrollment target sits among peer trials

29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03595228, the US trial registry maintained by the National Library of Medicine. NCT03595228 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.